Skip to Content
MilliporeSigma
  • Management of von Willebrand disease type 3 during pregnancy - 2 cases reports.

Management of von Willebrand disease type 3 during pregnancy - 2 cases reports.

European review for medical and pharmacological sciences (2013-11-21)
G Inocêncio, A Braga, S Azevedo, G Buchner
ABSTRACT

von Willebrand disease type 3, is an extremely rare condition. It can be severe and potentially life-threatening, particularly in pregnant women during labor and subsequently during early puerperium. Due to its rarity, there is no optimal treatment/management during pregnancy. We describe two cases of pregnant women with von Willebrand disease type 3, and its successful surveillance and treatment with Haemate P FVIII (human plasma-derived von Willebrand Factor-ristocetin co-factor associated with human coagulation factor VIII), during pregnancy, partum and puerperium. Daily prophylaxis with Haemate P FVIII in women with von Willebrand disease type 3, starting 2 hours before caesarean section until the 7th day of puerperium, associated with close analytical and clinical surveillance seems to be a safe clinical option.

MATERIALS
Product Number
Brand
Product Description

Human coagulation factor VIII concentrate, European Pharmacopoeia (EP) Reference Standard
Sign Into View Organizational & Contract Pricing
SKUPack SizeAvailabilityPriceQuantity
10 mg
In Stock
Details...
$81.70
$71.08
50 mg
In Stock
Details...
$329.00